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Many guidelines suggest that angiotensin-converting
enzyme inhibitors and angiotensin-II receptor antagonists
(collectively referred to as renin, angiotensin, aldosterone
system blockers (RAAS blockers)) are the preferred treatment
for hypertension in most patients with chronic kidney
disease (CKD). Improving the recognition of CKD with the
introduction of eGFR reporting was intended to have
more patients recognized with and treated for this disease.
To quantify this, we examined trends in RAAS-blocker
use over an 88-month period before and after routine
eGFR reporting in southwestern Ontario, Canada. An
intervention analysis with seasonal time-series modeling
on linked health administrative data for 45,361 ambulatory
residents with CKD (eGFR stages 3–5) older than 65 years
was performed with a primary outcome of RAAS-blocker
usage. The reporting of eGFR was associated with a
significant increase in the use of RAAS blockers, as the
prescription rate was 571 per 1000 patients with CKD prior to
reporting but improved to 607 per 1000 after reporting.
There was a significant increase in RAAS-blocker use
attributable to eGFR reporting of 19 per 1000 CKD patients.
Since about 8% of the adult population has CKD, this equates
to about 15,200 new patients receiving RAAS-blocker
treatment by 1 year after the introduction of eGFR reporting
in community laboratories. Thus, eGFR reporting contributes
to improved, guideline-appropriate care of older patients
with CKD.
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Moderate to severe chronic kidney disease (CKD; CKD stages
3–5 (ref. 1)) refers to an estimated glomerular filtration rate
(eGFR)o60 ml/min per 1.73 m2 and affects about 8% of the
adult population in North America.2 Multiple international
guidelines indicate that the use of angiotensin-converting
enzyme inhibitors and angiotensin-II receptor antagonists
(collectively referred to as renin, angiotensin, aldosterone
system blockers (RAAS blockers)) is the preferred treatment
option for hypertension in most patients with CKD.3,4
Despite these recommendations, in multiple jurisdictions a
significant number of patients with CKD are not taking
RAAS blockers (use ranges from 36 to 49%).5–8
This underuse has been attributed to an under-recognition
of CKD primarily in the primary care setting. To improve the
detection of CKD, multiple international societies now
suggest that kidney function be estimated with the use of
an equation, and that this eGFR result be reported along with
the serum creatinine.9–11 It is believed that eGFR reporting
removes the ‘guess work’ required to identify a patient as
having CKD when simply looking at the serum creatinine
in isolation. eGFR reporting has been shown to markedly
improve detection of CKD.12 Improving the recognition of
CKD with the introduction of eGFR reporting may mean
that more patients are treated with RAAS blockers. To study
this issue we examined trends in RAAS-blocker use after the
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introduction of eGFR reporting in southwestern Ontario,
Canada.
RESULTS
The number of patients, 66 years or older, who had moderate
to severe CKD (at least one eGFR o60 ml/min per 1.73 m2)
rose gradually during the study period, from 10,854 in early
2003 to 15,846 in early 2008. These patients had character-
istics that remained similar for the duration of the study
(Table 1). Just under one-third were diabetic and about 70%
were hypertensive.
Before the introduction of eGFR reporting, the use of
RAAS blockers increased slightly from early 2003 to late 2005
(571 per 1000 patients in late 2005). After the introduction of
eGFR reporting in January 2006, the rate of prescriptions for
these drugs increased suddenly and significantly. By early
2008, the rate of prescriptions had increased to 607 per 1000
(Figure 1). According to the model, the increase in RAAS-
blocker use attributable to eGFR reporting (o2) was 19 per
1000 CKD patients (P¼ 0.034). The increase in RAAS-
blocker use attributable to eGFR reporting in each 4-month
interval during the year 2006 (o1) was 4 per 1000 (P¼ 0.093).
Thus, even when accounting for the increasing trend in use
noted in the pre-eGFR reporting time period, the initiation
of eGFR reporting itself was associated with an almost 2%
Table 1 | Characteristics of patients with an eGFR o60ml/min per 1.73m2 (primary group)
Characteristic
Before eGFR reporting After eGFR reporting
January January January January January January
2003 2004 2005 2006 2007 2008
(n=10,854) (n=10,825) (n=13,094) (n=14,399) (n=15,175) (n=15,846)
Female (%) 65 63 64 64 63 63
Median eGFR 51 50 50 50 50 50
eGFR groups (%)
59–45 67 66 67 66 66 67
44–30 25 26 26 26 26 26
29–15 7 7 7 7 7 7
o15 1 1 1 1 1 1
Median age 79 79 79 79 79 79
Age groups (%)
66–70 13 13 14 14 15 15
71–75 21 21 21 21 21 20
76–80 26 26 26 25 24 24
81–85 21 22 22 23 23 22
X86 18 18 17 18 19 19
Diabetesa (%) 22 23 23 24 26 28
Hypertensionb (%) 70 70 70 70 71 71
History of MIc (%) 4 4 4 3 3 3
History of heart failured (%) 5 5 4 4 4 3
Medications usage (%)
Thiazide diuretics 31 34 35 36 37 37
a-Blockers 4 4 4 4 4 3
Ca2++ channel blockers 31 32 32 34 35 34
b-Blockers 32 33 35 35 36 36
Vasodilators 2 1 1 1 1 1
Loop diuretics 25 25 24 23 23 22
Potassium sparing diuretics 14 13 12 12 11 10
Abbreviations: eGFR, estimated glomerular filtration rate (in ml/min per 1.73m2); MI, myocardial infarction.
The characteristics of the last interval are presented here.
The presence of comorbidities was determined by using data for 3 years preceding cohort entry.
aThe presence of this diagnosis was determined with the use of the Ontario Diabetes Database, according to Hux et al.26
bThe presence of this diagnosis was determined with the use of an algorithm defined by Tu et al.27
cThe presence of this diagnosis was determined by any of the following codes (ICD-9: 410 ; ICD-10-CA: I21).
dThe presence of this diagnosis was determined by any of the following codes (ICD-9: 428; ICD-10-CA: I50).


























Figure 1 |Age- and sex-standardized rate of RAAS-blocker use.
Each bar represents a 4-month interval. The solid line with 95%
confidence intervals represents the forecasted rate of RAAS-blocker
use using an autoregressive integrated moving average model. CKD,
chronic kidney disease; eGFR, estimated glomerular filtration rate;
RAAS blocker, renin, angiotensin, aldosterone system blocker.
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increased use of RAAS blockers among CKD patients.
Appropriateness of model fit was confirmed using suitable
tests (Figure 2).
Secondary outcomes
The introduction of eGFR reporting had no significant
impact on incident RAAS-blocker use among those patients
with moderate to severe CKD and no prior history of RAAS-
blocker use. Just before the introduction of eGFR reporting
RAAS-blocker use was 39 per 1000 patients, whereas by early
2008 the rate was 45 per 1000 patients. This group was 12%
diabetic and 54% hypertensive. The group of patients, 66
years or older, whose eGFR was between 60 and 89 ml/min
per 1.73 m2 had a median eGFR of 73 ml/min per 1.73 m2.
They had less comorbidities and were slightly younger than
the moderate to severe CKD group. After the introduction of
eGFR reporting in January 2006, the rate of prescriptions for
RAAS blockers also increased significantly from 443 in late
2005 to 469 per 1000 patients in early 2008. According to the
model, the increase in RAAS-blocker use attributable to
eGFR reporting was 21 per 1000 CKD patients (Po0.0001).
There was no significant increase in RAAS-blocker use in the
normal kidney function group, i.e., those with an eGFR of
90 ml/min per 1.73 m2 or greater.
Additional observations
Using the same analytic strategy, no change was noted in the
use of proton pump inhibitors in those with an eGFR
o60 ml/min per 1.73 m2 or those with an eGFR between 60
and 90 ml/min per 1.73 m2, which could be attributed to
eGFR reporting, nor was there any change in the other
medications studied: thiazide diuretics, a-blockers, calcium
channel blockers, b-blockers, vasodilators, loop diuretics, and
potassium sparing diuretics.
DISCUSSION
Our results indicate that eGFR reporting was associated with
improved, guideline-appropriate, health-care delivery to
older patients with CKD. After the introduction of eGFR
reporting, RAAS-blocker use suddenly increased by about 2%
in patients with CKD. As expected, there was no effect noted
on those with normal kidney function.
This result is similar to observations made in two previous
studies. After the introduction of eGFR reporting, Wyatt
et al.13 noted a 1.9% increase in RAAS-blocker use among
patients with CKD in an urban Veterans Affairs primary care
outpatient population (from 65 to 67%; Po0.0001).
Chaudhry et al.14 noted a 6% increase in RAAS-blocker use
in British Columbia, Canada (from 23 to 29%; Po0.03).
These data indicate that eGFR reporting increases the
recognition of CKD, which in turn results in more patients
treated with RAAS blockers.15 However, a recent study by
Hemmelgarn et al.16 did not find an association between
eGFR reporting and RAAS-blocker use. This lack of impact
may have been related to the decreasing use of these
medications noted in the pre-eGFR reporting time period
and/or the extensive use of RAAS blockers among the
patients in this study (e.g., 77.5% of participants with
diabetes and proteinuria).
It may be assumed that the increase of 2% we have noted,
even if it is statistically significant, is modest. However, at the
population level this represents quite a large effect. For
example, in the province of Ontario (according to the 2006
Canadian Census) there are about 10 million adult residents.
If 8% of these individuals have moderate to severe CKD
(stages 3–5), then there are 800,000 people with this
condition in the community.2 Our results would indicate
that eGFR reporting resulted in about 15,200 more people
being treated with guideline-approved therapy over 1 year.
It is important to note that no impact was seen when
we restricted our CKD population to those who had not
used a RAAS blocker in the past 1 year. This group likely
represents individuals who could not tolerate or comply with
RAAS-blocker use and also includes patients for whom
RAAS-blocker use is not indicated (e.g., those without hyperten-
sion). Furthermore, as this group had smaller numbers, this
may have resulted in some degree of variability that our
model could not account for, resulting in a nonsignificant
finding.
Policy makers will be interested in our results for several
reasons. First, in Ontario, changes in practice occurred in the
absence of a resource-intensive educational effort on the
interpretation of eGFR. Although it can be debated whether
the change occurred as a result of the eGFR value or the
laboratory prompt itself, this study does demonstrate that
simple changes to laboratory reporting practices on their own
can have an important influence on the quality of patient
care. Applying similar reporting strategies to other areas of
medicine may have similar beneficial effects, although this
remains to be studied. Second, more accurate equations to
estimate kidney function have recently been developed, and
new staging systems for CKD, which incorporate proteinuria
measurements, are being proposed.17 Before their adoption,
policy makers might now consider how changing the
















P-values for Ljung–Box statistic
Figure 2 |Confirmation of model appropriateness. Residual
autocorrelation was not detected using Ljung–Box w2-test
statistics for different lag periods; residual autocorrelation was
not detected by visual assessment of standardized residual
autocorrelation function plot. ACF, autocorrelation function.
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‘definition’ of CKD in the community will influence the
effects of eGFR reporting as observed here.
The greatest strength of this study is our large diverse
sample and robust methodology. We studied more than
40,000 CKD (stages 3–5) patients over the course of the study.
We used time-series analysis, a more robust and precise
methodology than a traditional pre-post study design.18 The
use of this population and study design helps protect against
other secular and demographic changes that may affect other
studies. Our signal was unique to RAAS blockers. There was,
as expected, no impact of eGFR reporting on the use of other
medications such as thiazide diuretics, a-blockers, calcium
channel blockers, b-blockers, vasodilators, loop diuretics, and
potassium sparing diuretics. This strengthens the assertion
that eGFR reporting had a specific impact on RAAS blockers
and not on all medications. Furthermore, the signal was
isolated to those with mild and moderate kidney dysfunction,
with no effect noted in those with normal kidney function.
This demonstrates that there was specific impact on those
who were identified as having abnormal kidney function
according to the laboratory prompt. These two observations
indicate that eGFR reporting resulted in improved recogni-
tion and adherence to CKD guidelines.
However, limitations of our research approach bear
consideration. RAAS blockers are typically used to reduce
proteinuria and blood pressure in patients with CKD;
however, the rationale for the use of RAAS blockers was
not recorded in our data sets. The baseline blood pressures or
degree of proteinuria have not been captured for this patient
population. In addition, there are other reasons (e.g.,
congestive heart failure, myocardial infarction, or diabetes)
for prescribing RAAS blockers. However, there was no major
change in our patient comorbidities over the course of the
study. This means that the change we noted is not related
to changes in a particular subgroup of CKD patients. Other
contemporaneous educational efforts (e.g., guidelines, edu-
cation programs) could have influenced the prescription rate.
However, on extensive review of the literature and in
discussion with physicians from around the province, no
such efforts from the government, pharmaceutical industry,
or other organizations were identified that coincided with the
observed changes in RAAS-blocker use. We could not reliably
assess whether there was an exaggerated rate of adverse events
such as hyperkalemia or acute kidney injury after the increase
in RAAS-blocker use, as there were too few events in
administrative data to allow for meaningful analysis. Because
of insufficient sample size, we could not reliably examine
RAAS-blocker use in those with an eGFR o30 ml/min per
1.73 m2 or assess other outcomes such as mortality and the
development of end-stage renal disease.
In conclusion, these results inform the debate as to the
utility of a new method of kidney function reporting. This
study demonstrates that the introduction of eGFR reporting
resulted in improved adherence to CKD guidelines. Patient
care has improved under the assumption that the guidelines
are correct. Future work should focus on understanding the




We conducted a population-based, time-series analysis using health-
care databases in southwestern Ontario, Canada, from 1 January
2003 to 30 April 2008. All residents received universal access to
hospital and physician services, and those over the age of 65 years
received coverage for prescription medications such as RAAS
blockers. Coverage for medical services and medications from a
single provincial payer provided a comprehensive set of health
administrative data that have been validated in previous epidemio-
logic studies.19–23 We created and followed a prespecified protocol,
and obtained ethics approval from the institutional review board at
Sunnybrook Health Sciences Centre, Toronto, Canada.
Intervention
In January 2006, Ontario medical laboratories began adding eGFR
results (using the abbreviated MDRD (Modification of Diet in Renal
Disease) study equation24) to serum creatinines on their laboratory
reports. This change affected all adult outpatient tests. Hospital-based
laboratories were not required to report eGFR. This change in
reporting was implemented without a concurrent educational effort
at the provincial level. In particular, no guidance was delivered to
physicians about appropriate treatments for these patients. However,
all eGFRs were presented with a laboratory prompt that included an
explanation of eGFR ranges (Table 2). Medical laboratories continued
to report a serum creatinine level along with reference ranges.
Data sources
Outpatient prescription medications dispensed to Ontario residents
65 years of age and older are accurately recorded in the Ontario
Drug Benefits Program (ODB) database.25 Information about all
Ontario hospitalizations is recorded in the Canadian Institute for
Health Information Discharge Abstract Database. Vital statistics
including dates of birth and death and place of residence are
recorded in the Registered Persons Database. Individuals in Ontario
with diabetes are recorded in the Ontario Diabetes Database using a
validated algorithm.26 Hypertension was identified by following a
validated algorithm developed by Tu et al.27 Gamma-Dynacare is the
Table 2 | Estimated glomerular filtration rate (eGFR) reporting
laboratory prompts from Gamma-Dynacare for patients of
varying degree of chronic kidney disease
eGFRa 90–120 Normal eGFR.
eGFRa 60–89 Slightly reduced eGFR is seen in B30% of adults
20 years or older. Rule out kidney damage in those at
high risk for chronic kidney disease.
eGFRa 30–59 Consistent with moderate chronic kidney disease if result
confirmed by repeat measurement, with persistence for
3 months or more.
eGFRa 15–29 Consistent with severe chronic kidney disease. Consider
nephrology referral.
eGFRa o15 Consistent with kidney failure.
Reports followed by: For African Canadians, the reported eGFR should be multiplied
by a factor of 1.21 and reinterpreted accordingly.
Standardized serum creatinine is in widespread use throughout Ontario.29
aeGFR measured by abbreviated MDRD (Modification of Diet in Renal Disease) study
equation in ml/min per 1.73m2.
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largest outpatient laboratory service provider in southwestern
Ontario. We archived all serum creatinine tests performed at
Gamma-Dynacare since January 2002 in a database. The four-
variable MDRD equation24 was applied to each serum creatinine
value to determine an individual’s eGFR. All serum creatinine values
for the period of interest were standardized for use in the MDRD
equation.28 All the databases were linked with encrypted, unique
identifiers (10-digit health-card numbers).
Identification of patients and outcomes
We divided each year of the study period into three 4-month intervals
(January through April, May through August, and September
through December). In total, this resulted in 16 consecutive intervals,
9 before the reporting of eGFR, 3 the year eGFR reporting was
adopted, and 4 after the full adoption of eGFR reporting. We chose
to use 4-month intervals because the Ontario Drug Benefit Program
will not reimburse prescriptions exceeding 100 days in duration.
We examined the records of patients 66 years of age or older, which
ensured that all individuals were eligible for a full year of prescription
drug coverage before being considered for the study.
To identify CKD patients, we identified all individuals in the
ambulatory renal database at the beginning of each interval who met
the prespecified eGFR cutoff. Our primary group was patients with
moderate to severe (stages 3, 4, and 5) CKD, i.e., those with an eGFR
o60 ml/min per 1.73 m2 at least once in the past year. We excluded
all patients who were on dialysis or had received a prior kidney
transplant. As a secondary outcome, incident use of RAAS blockers
was assessed by limiting this group to those who had no history
(in the past 1 year) of RAAS-blocker use.
Also secondarily, we followed up those with mild kidney
dysfunction and normal kidney function. Among those patients with
mild kidney dysfunction, we hypothesized that they may be affected
by eGFR reporting as their reduced kidney function was presented to
their physicians (Table 2). We defined this group as those who had an
eGFR between 60 and 89 ml/min per 1.73 m2 at least once in the past
year. Because we did not have other laboratory data we could not
confirm that these patients met the true Kidney Dialysis Outcome
Quality Initiative stage 2 definition, as this would require other
markers of damage, including abnormalities in blood or urine tests or
imaging studies.1 We hypothesized that patients with normal kidney
function (as identified by the prompt, Table 2) would be unaffected
by eGFR reporting. We defined this group as those who had an eGFR
490 ml/min per 1.73 m2 at least once in the past year.
For each 4-month interval, we identified all patients with at least
one prescription for a drug of interest.
Our primary outcome was the age- and sex-standardized prescription
rate for RAAS blockers (either angiotensin-converting enzyme inhibitors
and/or angiotensin-II receptor antagonists) per 1000 CKD patients.
To assess the specificity of the impact of eGFR reporting, we used
a tracer outcome of proton pump inhibitors. We expected eGFR
reporting to have no impact on proton pump inhibitor prescrip-
tions, because this medication is unrelated to CKD. Similarly, we did
not expect eGFR reporting to impact a list of other medications, as
unlike RAAS blockers these medications did not receive emphasis in
Canadian guidelines for the treatment of CKD: thiazide diuretics,
a-blockers, calcium channel blockers, b-blockers, vasodilators, loop
diuretics, and potassium sparing diuretics.
Statistical analysis
We used interventional autoregressive integrated moving average
models with a seasonal autocorrelation parameter to assess whether
eGFR reporting significantly affected the age- and sex-standardized
rate of prescriptions per 1000 CKD patients. This type of analysis
can account for the correlated nature of the data. First-order
differencing was used to create a stationary time series with constant
mean and variance over time. Two intervention parameters were
included in the Autoregressive Integrated Moving Average time
series model to estimate the effect of eGFR reporting on RAAS-
blocker use per 1000 patients (RAAS-blocker use rate): a ramp
function at each time period during the year of eGFR adoption
(call this intervention parameter ‘o1’, the covariate associated with
o1 was equal to 1 for April 2006, 2 for August 2006, and 3 for
December 2006) and a different step function for the time points
after this year (call this intervention parameter ‘o2’, the covariate
associated with o2 was equal to 1 for all periods between April 2007
and April 2008, and 0 otherwise). A ramp function was chosen for
the three time periods in 2006, because in April 2006 approximately
1/3 of the patients with eGFRo60 ml/min per 1.73 m2 were subject
to eGFR reporting (see ‘Identification of patients and outcomes’
subsection); similarly, approximately 2/3 of the patients with eGFR
o60 ml/min per 1.73 m2 in August 2006 were subject to eGFR
reporting, and 3/3 of the patients with eGFRo60 ml/min per 1.73 m2
in December 2006 were subject to eGFR reporting. Therefore, it was
reasonable to expect that the effect of eGFR reporting on RAAS-
blocker use rate would be detected incrementally over the year 2006.
Parameter o1 can be interpreted as the change in RAAS-blocker use
rate for a one-unit change in time interval for time intervals April,
August, and December 2006. Parameter o2 is the difference in
average RAAS-blocker use rate between April 2007 and April 2008
(four time periods in total), to the average RAAS-blocker use rate
between April 2003 and December 2005 (nine time periods in total).
If o2 was found to be significantly different from 0 using a two-sided
Z-test, there was a significant intervention effect. Once a model was
fit, we confirmed model appropriateness by examining the auto-
correlation function at different lag periods using the Ljung–Box
w2-statistic; autocorrelation functions were visually examined to detect
residual autocorrelation. We forecasted intra- and post-intervention
values along with 95% confidence intervals. All P-values were two-
sided and we interpreted a value o0.05 as statistically significant.
We performed our analyses using R for Windows, Version 2.10.0
(R Foundation for Statistical Computing).
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This study was supported by grants provided by the Canadian
Institutes of Health Research (CIHR) and the Academic Medical
Organization of Southwestern Ontario. AKJ was supported by
a Health Professional Research Fellowship from the CIHR.
AXG was supported by a Clinician Scientist Award from the CIHR.
The Institute for Clinical Evaluative Sciences received funding from
the Ontario Ministry of Health and Long-term Care. The opinions,
results, and conclusions reported in this paper are those of the
authors, and are independent from the funding sources. We thank
Barbara Jones, Jeff Lamond, and the late Milton Haines for their
help in providing access to Gamma-Dynacare laboratory data.
This archive has been instrumental for many projects including
this one.
REFERENCES
1. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice
guidelines for chronic kidney disease: evaluation, classification, and
stratification. Ann Intern Med 2003; 139: 137–147.
1252 Kidney International (2012) 81, 1248–1253
or ig ina l a r t i c l e AK Jain et al.: eGFR reporting increases RAAS-blocker use
2. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease
in the United States. JAMA 2007; 298: 2038–2047.
3. Levin A, Hemmelgarn B, Culleton B, et al., for the Canadian Society of
Nephrology. Guidelines for the management of chronic kidney disease.
CMAJ 2008; 179: 1154–1162.
4. KDOQI. Clinical Practice Guidelines and Clinical Practice
Recommendations for Diabetes and Chronic Kidney Disease. Am J
Kidney Dis 2007; 49: S12–154.
5. Bailie GR, Eisele G, Liu L et al. Patterns of medication use in the RRI-CKD
study: focus on medications with cardiovascular effects. Nephrol Dial
Transplant 2005; 20: 1110.
6. Hsu C, Bates DW, Kuperman GJ et al. Blood pressure and angiotensin
converting enzyme inhibitor use in hypertensive patients with chronic
renal insufficiency. Am J Hypert 2001; 14: 1219–1225.
7. Israni A, Korzelius C, Townsend R et al. Management of chronic kidney
disease in an academic primary care clinic. Am J Nephrol 2003; 23: 47–54.
8. Kausz AT, Khan SS, Abichandani R et al. Management of patients with
chronic renal insufficiency in the Northeastern United States. J Am Soc
Nephrol 2001; 12: 1501.
9. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of
chronic kidney disease: a position statement from Kidney Disease:
Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–2100.
10. Levin A, Mendelsohn D Care and Referral of Adult Patients with Reduced
Kidney Function: position paper from the Canadian Society of
Nephrology. Canadian Society of Nephrology. ohttp://www.csnscn.ca/
atf/cf/%7Bfd785d1c-e27a-489e-be3a-c75d43a753f1%7D/CSN%
20POSTION%20PAPER%20SEPT2006.PDF4, accessed on 14 March 2012.
11. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative.
ohttp://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm4,
accessed on 14 March 2012.
12. Akbari A, Swedko PJ, Clark HD et al. Detection of chronic kidney disease
with laboratory reporting of estimated glomerular filtration rate and
an educational program. Arch Intern Med 2004; 164: 1788–1792.
13. Wyatt C, Konduri V, Eng J et al. Reporting of estimated GFR in the primary
care clinic. Am J Kidney Dis 2007; 49: 634–641.
14. Chaudhry M, Tregillus V, Platt H et al. Integrated strategies for CKD
identification in BC: improved testing and care without increase in visitis
to nephrologists. Canadian Society of Nephrology Conference
Proceedings. 2005.
15. Rothberg MB, Kehoe ED, Courtemanche AL et al. Recognition and
management of chronic kidney disease in an elderly ambulatory
population. J Gen Intern Med 2008; 23: 1125–1130.
16. Hemmelgarn BR, Zhang J, Manns BJ et al. Nephrology visits and health
care resource use before and after reporting estimated glomerular
filtration rate. JAMA 2010; 303: 1151–1158.
17. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate
glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
18. Box GEP, Tiao GC. Intervention analysis with applications to economic
and environmental problems. J Am Stat Assoc 1975; 70: 70–79.
19. Hux JE, Ivis F, Flintoft V et al. Diabetes in Ontario: determination of
prevalence and incidence using a validated administrative data
algorithm. Diabetes Care 2002; 25: 512–516.
20. Levy AR, O’Brien BJ, Sellors C et al. Coding accuracy of administrative
drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol
2003; 10: 67–71.
21. Jong P, Gong Y, Liu PP et al. Care and outcomes of patients newly
hospitalized for heart failure in the community treated by cardiologists
compared with other specialists. Circulation 2003; 108: 184–191.
22. Al-Omran M, Tu JV, Johnston KW et al. Outcome of revascularization
procedures for peripheral arterial occlusive disease in Ontario
between 1991 and 1998: a population-based study. J Vasc Surg 2003;
38: 279–288.
23. Juurlink D, Preyra C, Croxford R et al. Canadian Institute for Health
Information Discharge Abstract Database: A Validation Study. Institute for
Clinical Evaluative Sciences: Toronto, 2006.
24. Levey AS, Greene T, Kusek JW et al. A simplified equation to predict
glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;
11: 155A.
25. Levy AR, O’Brien BJ, Sellors C et al. Coding accuracy of administrative
drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol
2003; 10: 67–71.
26. Hux JE, Ivis F, Flintoft V et al. Diabetes in Ontario: determination of
prevalence and incidence using a validated administrative data
algorithm. Diabetes Care 2002; 25: 512–516.
27. Tu K, Campbell NRC, Chen XL et al. Accuracy of administrative
databases in identifying patients with hypertension. Open Med 2007; 1:
e3–e5.
28. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine
values in the modification of diet in renal disease study equation
for estimating glomerular filtration rate. Ann Intern Med 2006; 145:
247–254.
29. Coresh J, Astor BC, McQuillan G et al. Calibration and random variation of
the serum creatinine assay as critical elements of using equations to
estimate glomerular filtration rate. Am J Kidney Dis 2002; 39: 920–929.
Kidney International (2012) 81, 1248–1253 1253
AK Jain et al.: eGFR reporting increases RAAS-blocker use o r ig ina l a r t i c l e
